SCHEMBL22773249

SCHEMBL22773249

COc1cc(C(=O)N2CCC(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc2c1CCC(=O)N2

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 2/20 0.42
▸ NR3C1 P04150 1/20 0.42
▸ PGR P06401 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ PKM P14618 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HSD11B1 P28845 4/20 0.40
▸ SMYD3 Q9H7B4 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ MAPK7 Q13164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22491371 0.91 NR3C1 (0.44) KCNH2NR3C1PGRSLC6A4PDE3B
SCHEMBL22491381 0.89 MGLL (0.39) KCNH2MAPTSMYD3HTTSLC6A3
SCHEMBL22773209 0.80 DRD2 (0.39) SMYD3
SCHEMBL22773221 0.77 MGLL (0.57) NR3C1PGRMAPTLMNAALDH1A1
SCHEMBL22491554 0.77 MGLL (0.57) NR3C1PGRMAPTLMNAALDH1A1
SCHEMBL22491415 0.77 MGLL (0.57) NR3C1PGRMAPTLMNAALDH1A1
SCHEMBL29734481 0.77 MGLL (0.57) NR3C1PGRMAPTLMNAALDH1A1
SCHEMBL22773220 0.76 MGLL (0.55) NR3C1PGRMAPTHSD11B1LMNA
SCHEMBL22773222 0.76 MGLL (0.55) NR3C1PGRMAPTHSD11B1LMNA
SCHEMBL22773208 0.76 MGLL (0.55) NR3C1PGRMAPTHSD11B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 — — US claimed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 — — EP claimed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 — — US claimed
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 — — US disclosed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 — — EP disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 — — US disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420961-B2 Heterocyclic compounds LPXN, MLX, CCNY KCNH2 578/4885NR3C1 3049/4885PGR 1928/4885
US-20200392125-A1 HETEROCYCLIC COMPOUNDS LPXN, MLX, CCNY KCNH2 578/4885NR3C1 3049/4885PGR 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback